Is Lantheus Holdings, Inc. (LNTH) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 12.6% / 30% | 7.3% / 30% | 7.6% / 30% | 1.52% / 5% | ✓ HALAL |
| DJIM | 12.6% / 33% | 7.3% / 33% | 7.6% / 33% | 1.52% / 5% | ✓ HALAL |
| MSCI | 27.8% / 33% | 16.1% / 33% | 16.8% / 33% | 1.52% / 5% | ✓ HALAL |
| S&P | 12.6% / 33% | 7.3% / 33% | 7.6% / 33% | 1.52% / 5% | ✓ HALAL |
| FTSE | 27.8% / 33% | 16.1% / 33% | 16.8% / 50% | 1.52% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 61.1% | |
| Operating Margin | 19.1% | |
| Net Margin | 15.2% | |
| Return on Equity (ROE) | 21.4% | |
| Return on Assets (ROA) | 9.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $390M |
| Free Cash Flow | $349M |
| Total Debt | $619M |
| Debt-to-Equity | 57.2 |
| Current Ratio | 2.7 |
| Total Assets | $2.2B |
Price & Trading
| Last Close | $76.36 |
| 50-Day MA | $72.41 |
| 200-Day MA | $64.97 |
| Avg Volume | 942K |
| Beta | -0.1 |
|
52-Week Range
$47.25
| |
About Lantheus Holdings, Inc. (LNTH)
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Purification Calculator
As a halal stock with 1.52% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Lantheus Holdings, Inc. (LNTH) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Lantheus Holdings, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Lantheus Holdings, Inc.'s debt ratio?
Lantheus Holdings, Inc.'s debt ratio is 12.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 27.8%.
Does Lantheus Holdings, Inc. require dividend purification?
Yes, Lantheus Holdings, Inc. has an impermissible income ratio of 1.52%, which means 1.52% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Lantheus Holdings, Inc.'s key financial metrics?
Lantheus Holdings, Inc. has a market capitalization of $4.8B, trailing P/E ratio of 21.8, and revenue of $1.5B. The company maintains a gross margin of 61.1% and a net margin of 15.2%. Return on equity stands at 21.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.